Summary:
- The article discusses clinical findings suggesting that the presence of even a single "silent" (asymptomatic) lesion on an MRI scan may be a sufficient clinical indicator to justify escalating disease-modifying therapy in patients with Multiple Sclerosis (MS).
- It highlights the shift toward more proactive treatment strategies, emphasizing that subclinical disease activity detected via neuroimaging is a critical metric for preventing long-term disability and managing MS progression.